Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02697188 · ClinicalTrials.gov registry record · Phase 2
Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men
A Phase 2 study, sponsored by Clarus Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT02697188: Completed Phase 2 study, sponsored by Clarus Therapeutics.
NCT02697188 is a Phase 2 study that has completed, run by Clarus Therapeutics. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02697188, a Phase 2 study, has completed, sponsored by Clarus Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Determine the serum pharmacokinetic profile for two oral formulations of T-esters (one TE and one TU) administered once -(QD) and twice-daily (BID) to hypogonadal men.
Primary Outcome
The objective of the study was to determine the single day serum pharmacokinetic profile for two oral formulations of T-esters (one TE and one TU formulation) administered once- and twice-daily to hypogonadal men.
Interventions
- DRUG Testosterone enanthate
- DRUG Testosterone undecanoate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
What the finished NCT02697188 record still lists
NCT02697188 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Testosterone enanthate is the first listed.
NCT02697188 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02697188 about?
NCT02697188 is a clinical study titled "Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men". Determine the serum pharmacokinetic profile for two oral formulations of T-esters (one TE and one TU) administered once -(QD) and twice-daily (BID) to hypogonadal men.
What is the current status of trial NCT02697188?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2007-11. Estimated completion is 2008-04.
What interventions are being tested in trial NCT02697188?
The interventions under investigation include: Testosterone enanthate (DRUG), Testosterone undecanoate (DRUG).
Who is sponsoring clinical trial NCT02697188?
This trial is sponsored by Clarus Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02697188's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia